Pardon, we have upgraded and moved this topic here
What follows has not been updated and will not be updates, but could still be useful
Relapsed / Refractory
Studies GROUPED BY:
 TOPIC SEARCH Drug Resistance and Lymphoma in ClinicalTrials.gov |
Clinical Trials for Refractory Lymphoma
Goal: Treating the disease using investigational therapies or new combinations of
therapies that that may overcome drug resistance. NOTE: By definition, clinical trials are investigational, and it is therefore not known if the goals of treatments will be realized.
What's New
.gif) |
Study of interest: Dendritic Cell Vaccine study
at Mayo Clinic for lymphoma - for most types
|
|
Study of interest: Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy | Discussion
|
Monoclonal Antibody
Monoclonal antibodies are man-made antibodies (proteins) that target receptors on lymphoma cells.
Return to top
|
Rituxan versus Bexxar at Relapse
Condition: Relapsed Follicular Non-Hodgkin's Lymphoma
|
|
*
Condition: B-cell lymphomas, including CLL
TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape | PubMed
TOPIC SEARCH Safety or Toxicity - PubMed
|
Novel Chemotherapy Agents
Monoclonal antibodies are man-made antibodies (proteins) that target receptors on lymphoma cells.
Return to top
novel chemotherapy agent - similar to anthracyclines
|
Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents
Condition: Third line Relapsed Aggressive Lymphoma, Non-Hodgkin
|
Return to top
Novel Targeted Agents
Drugs that target pathways that may have high specificity to Lymphoma cells.
Return to top
|
Brentuximab Vedotin Before Autologous Stem Cell Transplant for Hodgkin Lymphoma http://1.usa.gov/p48iQa
|
|
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory
Follicular Lymphoma http://clinicaltrials.gov/ct2/show/NCT00901069
|
|
All CLL/Lymphoma studies incorporating Azacytidine http://bit.ly/2qDAXc
|
|
BMS-247550 (epothilone)
Conditions: Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma -
including grade 3 follicular
TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - ASCO | Medscape | PubMed
TOPIC SEARCH Safety or Toxicity - ASCO | PubMed
|
|
Btk Inhibitor in Recurrent B Cell Lymphoma
Conditions: Relapsed or DLBCL (non-GCB subype)
Details: http://bit.ly/9zOLVV
|
Combining novel chemo and targeted agents
|
SDX-105 (Bendamustin/Treanda™) with Bortezomib (Velcade)
Condition: Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL
|
|
MGCD0103 Given Three Times Weekly
Condition: Relapsed or refractory DLBCL or Follicular Lymphoma
|
|
CD3 immunotoxin therapy of cutaneous T cell lymphoma http://bit.ly/b8Wvma
This novel immunotoxin has dramatic clinical activity even at the lowest dose in CTCL patients and merits applications at higher doses in CTCL and other CD3+ T cell leukemia/lymphoma patients. The lymphodepletion with recovery of T regulatory cells suggests the drug may be beneficial for immunosuppression of T cell autoimmune disorders.
Clinical trials: http://bit.ly/cz7jlZ
|
Return to top
Novel Immunotherapy Protocols
experimental ways to activate the immune system to target Lymphoma cells.
Return to top
|
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma http://bit.ly/farwZY
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with residual, relapsed, or refractory B-cell Non-Hodgkin's lymphoma
Also see: Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity
http://clincancerres.aacrjournals.org/content/11/13/4955.full
|
|
Wilm's Tumor 1 Protein Vaccine ... for relapsed NHL after allo SCT http://bit.ly/cGFFDG
Patients with the blood antigen HLA-A2 and the WT1 cancer protein who have persistent or recurrent blood cancers after [allo] stem cell transplantation.
Background: "Most patients [with blood cancers] including NHL have a protein called Wilm's Tumor 1 (WT1) in their cancer cells. This protein is thought to be able to influence the growth of these cancers.
A vaccine made with the WT1 protein may boost the immune system to help fight these cancers in patients whose cancer cells contain the protein."
|
|
Donor Natural Killer Cell Infusion, Rituxan, Aldesleukin (IL-2), and Chemotherapy
Condition: relapsed cd-20 positive NHL or CLL
|
|
Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Hematological Malignancies
|
|
Intratumoral Injection of CPG 7909, Combined With Low dose Local Radiation
NOTE: Study closed as of March 2008, might reopen before end of year.
Condition: low-grade B-cell lymphoma of any initial stage or mycosis fungoides of stage IB-IVA. B-cell lymphoma patients must have failed at least one prior treatment. Mycosis fungoides patients must have failed or have been intolerant of at least 2 topical or one systemic treatment.
|
combining radiotherapy with radioimmunotherapy
|
Radiation and Bexxar
Condition: Previously treated follicular lymphoma with > 5 cm nodal tumors.
|
targeted therapy: delivering chemotherapy with antibody
|
A Study Of anti-cd22 immunoconjugate (IO) Plus Rituximab
http://bit.ly/hBqoFd
Condition: For Relapsed/Refractory Aggressive NHL Patients Who Are NOT Candidates For Intensive High-Dose Chemotherapy.
|
IO is a humanized anti-CD22 antibody conjugated to calicheamicin, a cytotoxic agent (antibody with chemo attached). IO targets CD22, which is expressed in the majority of B-cell NHL.
2010 ASH report on IO: Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy http://ash.confex.com/ash/2010/webprogram/Paper33326.html
combining targeted agents with radioimmunotherapy
|
Combined Weekly Velcade and Bexxar
Condition: Relapsed or Refractory Follicular Lymphoma
|
utilizing genetically altered t-cells to target lymphoma cells
|
Cellular Immunotherapy using Genetically Modified Autologous CD20-specific CD8+ T Cell Clones
And:
|
|
Cellular Immunotherapy With Autologous CD8+ Cytotoxic T Lymphocyte Clones After Chemo (Cyclophosphamide, Vincristine, and Prednisone)
Condition: Relapsed CD20+ follicular lymphoma
|
genetically altered t-cells to target lymphoma cells
novel immune modulating / targeted agent
|
Lenalidomide (Revlimid)
Condition: Relapsed or Refractory Hodgkin Disease
|
|
Lenalidomide (Revlimid)
Conditions: Refractory CLL or SLL
TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - ASCO | Medscape | PubMed
TOPIC SEARCH Safety or Toxicity - ASCO | PubMed
|
combines Rituxan with an immune modulating agent
-
Rituxan and/or Lenalidomide (Revlimid)
Condition: follicular lymphoma - relapsed following Rituxan-based combination therapy
TOPIC SEARCH: Mechanisms PubMed
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed
combines a targeted agent with rituxan immunotherapy
-
CCI-779 and Rituxan
Condition: Relapsed or Refractory Mantle Cell lymphoma
combines radioimmunotherapy with monoclonal antibody to treat challenging CNS lymphoma
-
Rituxan and Zevalin
Condition: Recurrent primary central nervous system (CNS) lymphoma
combines Rituxan and Radioimmunotherapy with an immune adjuvant
-
Rituxan and Zevalin and Cp7909 (an immune adjuvant)
Condition: Refractory and relapsed NHL (including transformed follicular NHL, MALT, MCL, and DLBCL)
combines Radioimmunotherapy with a second agent in T-cell and Hodgkins lymphomas
-
Yttrium-90 Radiolabeled Humanized Anti-Tac and Calcium-DTPA
Conditions: Tac-Expressing -
Cutaneous T Cell Lymphoma;
Hodgkin's Disease; Neoplasm;
Non Hodgkin's Lymphoma;
Peripheral T Cell Lymphoma
adoptive immunotherapy in EBV-positive lymphomas
-
LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody for Lymphoma
Condition: EBV-positive Lymphoma
Novel Chemo-immunotherapy protocols
Return to top
-
Vaccine with Interleukin-2 After Combination Chemotherapy
Condition: Previously treated, or untreated, Mantle Cell Lymphoma
Return to top
Stem Cell Transplant (SCT)-based protocols
Return to top
utilizing cord blood for stem cell graft
-
Conditions
Sponsor's website: http://stemexstudy.com/
TOPIC SEARCH Cord blood derived Stem Cell transplantation PubMed
standard SCT with cord blood derived cells
Umbilical Cord Blood Transplantation
Conditions:
High risk childhood non-Hodgkin's lymphoma;
Graft Versus Host Disease;
Leukemia;
Lymphoma;
Myelodysplastic (MDS) and myeloproliferative diseases
utilizing graft versus lymphoma affect
-
SCT Donor Stem Cell Transplant
Conditions:
Childhood Hodgkin's lymphoma;
Childhood non-Hodgkin's lymphoma; Leukemia;
Lymphoma; myelodysplastic and myeloproliferative diseases -
(eligible if relapse from Auto SCT)
the goal of treatment is to consolidate SCT with investigational vaccine therapy
-
Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation
Condition: recurrent grade 1-3 follicular lymphoma
Return to top
For DLBCL, not eligible or desiring Stem Cell Transplant (SCT)
-
Studies recruiting for DLBCL, not eligible for transplant http://bit.ly/aVbuVF
Return to top
Radioimmunotherapy and Stem Cell Transplant
Return to top
Radioimmunotherapy as part of conditioning for Stem Cell Transplantation
-
Rituxan/BEAM versus Bexxar/BEAM with Autologous Stem Cell Transplantation
Conditions: Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell NHL
also see protocol/0401
-
Bexxar followed by BEAM conditioning study and Autologous Stem Cell Transplant
Conditions: Relapsed Diffuse Large B-cell Lymphoma
-
Ongoing, but
-
Bexxar, Etoposide, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation
Conditions: Relapsed or Refractory non-Hodgkin's lymphoma
-
Bexxar Followed by Autologous Stem Cell Transplantation
Condition: Older patients with relapsed or refractory NHL
|
